- Home
- IRS vs XERS Comparison
IRS vs XERS Comparison
Compare IRS & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
IRS
IRSA Inversiones Y Representaciones S.A. Global Depositary Shares (Each representing ten shares of)
Current Price
Current Price
Company Overview
Basic Information| Metric | IRS | XERS |
|---|---|---|
| Founded | 1943 | 2005 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 1994 | 2018 |
Fundamental Metrics
Financial Performance| Metric | IRS | XERS |
|---|---|---|
| Price | $15.27 | $7.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $10.43 |
| AVG Volume (30 Days) | 177.6K | ★ 2.1M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | ★ 9.10% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.42 | N/A |
| Revenue | ★ $370,153,377.00 | $266,137,000.00 |
| Revenue This Year | N/A | $44.37 |
| Revenue Next Year | N/A | $27.87 |
| P/E Ratio | $3.46 | ★ N/A |
| Revenue Growth | N/A | ★ 42.05 |
| 52 Week Low | $10.61 | $3.14 |
| 52 Week High | $17.29 | $10.08 |
Technical Indicators
Market Signals| Indicator | IRS | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 52.84 | 46.31 |
| Support Level | $14.80 | $6.85 |
| Resistance Level | $15.77 | $7.24 |
| Average True Range (ATR) | 0.59 | 0.28 |
| MACD | -0.07 | 0.09 |
| Stochastic Oscillator | 71.74 | 78.31 |
Price Performance
Historical ComparisonAbout IRS IRSA Inversiones Y Representaciones S.A. Global Depositary Shares (Each representing ten shares of)
IRSA Inversiones y Representaciones SA is engaged in a diversified business. The company's operating segments include Shopping Malls, which comprise lease and service revenues principally related to the rental of commercial and other spaces in the company's shopping malls; Offices, which include lease revenues and other service revenues related to office activities; Sales and Developments, which include the development, maintenance, and sales of undeveloped parcels of land and/or trading properties; Hotels, which mainly include revenues from rooms, catering, and restaurants; and others. The company generates the majority of its revenue from the Shopping Malls segment.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).